Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome
Key facts
- Who runs it
- Taipei Medical University Shuang Ho Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Oct 2022
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cardiopulmonary rehabilitation
- Health education
- Record updated
- 26 March 2025
- Why it stopped
- Unable to get funds
Who can take part
- Age
- 20 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- be willing and able to provide written informed consent and comply with all procedures required by the protocol
- be 20 - 80 years of age at the time of signing the Informed Consent Form
- diagnosed with COVID-19 with PCR and admitted with at least moderate COVID-19 disease (with clinical symptoms or imaging evidence of low respiratory tract involvement)
- diagnosed with COVID-19 for over 4 weeks but less than 2 years with fatigue, shortness of breath, cough, weakness, or impairments of activities of daily life
- able to cooperate with the rehabilitation programs and cycling
Who cannot take part
- Patients under 20-year-old or over 80-year-old, pregnant, prisoners
- Patients without national health insurance in Taiwan
- The patient cannot follow instructions or cycling
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In 2022, though the optimized acute medical treatment of COVID-19 was determined, patients often experience the sequelae (also known as post-acute COVID-19 syndrome, the patients might develop cough, breathlessness, fatigue, weakness, impaired activities of daily livings etc.). Until now, there is no consensus for post-acute COVID-19 syndrome management. Previously, the cardiopulmonary rehabilitation revealed significant benefits in heart failure or chronic obstructive pulmonary disease. The aims of the study are demonstrating the benefits and safety of cardiopulmonary rehabilitations in patients previously admitted to hospital because of COVID-19 with sequelae.
The 2 groups in the trial
- Cardiopulmonary rehabilitation with health educationTreatment being tested
The participants will participate in cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total. Recommendations for individualized exercise prescription and lifestyle modification will be given to the participants as well.
Treatment: Cardiopulmonary rehabilitation and Health education
- Health educationExisting treatment, for comparison
The participants will be given recommendations for individualized exercise prescription and lifestyle modification.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 March 2025